Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

Inclusion Criteria: * Provision of informed consent before participating in the study * Diagnosed with type 2 diabetes (high blood sugar); HbA1c ≥ 7.2% and ≤10.0% * Subjects should be drug naïve * Women of childbearing potential who comply to use an adequate method of contraception to avoid pregnancy throughout the study \& who have a negative serum or urine pregnancy test Exclusion Criteria: * Subjects received Insulin therapy within one year of enrollment * Subjects who have severe uncontrolled hypertension * Subjects who have history of unstable or rapidly progressing renal disease * Subjects who have severe liver disease * Subjects who receiving treatment for Human immunodeficiency virus (HIV)